SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) released its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, hitting analysts’ consensus estimates of ($0.23), Zacks reports. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The firm had revenue of $17.73 million during the quarter, compared to the consensus estimate of $17.71 million. SOPHiA GENETICS updated its FY 2025 guidance to EPS.
SOPHiA GENETICS Stock Up 0.3 %
Shares of SOPH stock opened at $3.11 on Thursday. SOPHiA GENETICS has a twelve month low of $2.70 and a twelve month high of $6.28. The stock has a market cap of $203.32 million, a P/E ratio of -2.85 and a beta of 1.03. The stock has a 50 day moving average of $3.58 and a 200 day moving average of $3.56. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12.
Analysts Set New Price Targets
Separately, Craig Hallum assumed coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a “buy” rating and a $11.00 price objective for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.40.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Further Reading
- Five stocks we like better than SOPHiA GENETICS
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Robinhood’s Rally: Is Global Expansion the Next Big Catalyst?
- Insider Trading – What You Need to Know
- Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
- Differences Between Momentum Investing and Long Term Investing
- Why Now Might Be the Best Time to Buy Target Stock
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
